JP2020517740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517740A5 JP2020517740A5 JP2020507722A JP2020507722A JP2020517740A5 JP 2020517740 A5 JP2020517740 A5 JP 2020517740A5 JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020517740 A5 JP2020517740 A5 JP 2020517740A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- pharmaceutical composition
- domain
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023065903A JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901462 | 2017-04-21 | ||
| AU2017901462A AU2017901462A0 (en) | 2017-04-21 | Agents for treating or preventing motor neurone disease and uses therefor | |
| AU2018900762 | 2018-03-08 | ||
| AU2018900762A AU2018900762A0 (en) | 2018-03-08 | “agents for treating disease and uses therefor” | |
| PCT/AU2018/050357 WO2018191786A1 (en) | 2017-04-21 | 2018-04-20 | Cd 14 antagonist antibodies for treating neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065903A Division JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517740A JP2020517740A (ja) | 2020-06-18 |
| JP2020517740A5 true JP2020517740A5 (https=) | 2021-05-27 |
Family
ID=63855469
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507722A Pending JP2020517740A (ja) | 2017-04-21 | 2018-04-20 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
| JP2023065903A Pending JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065903A Pending JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200148780A1 (https=) |
| EP (1) | EP3612566A4 (https=) |
| JP (2) | JP2020517740A (https=) |
| KR (1) | KR20200015477A (https=) |
| CN (1) | CN110831975A (https=) |
| AU (1) | AU2018255489B2 (https=) |
| IL (2) | IL309046B2 (https=) |
| WO (1) | WO2018191786A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019264996A1 (en) * | 2018-05-10 | 2020-11-26 | The Methodist Hospital | Methods for prognosis and management of disease |
| LT3618928T (lt) | 2018-07-13 | 2023-04-11 | Alector Llc | Anti-sortilino antikūnai ir jų panaudojimo būdai |
| EP3983441A1 (en) * | 2019-06-11 | 2022-04-20 | Alector LLC | Anti-sortilin antibodies for use in therapy |
| CN114450068A (zh) * | 2019-07-25 | 2022-05-06 | 因普利西特生物科学有限公司 | 用于治疗急性神经炎性损伤的方法和剂 |
| JP7701931B2 (ja) * | 2020-02-13 | 2025-07-02 | プリレニア ニューロセラピューティクス リミテッド | プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法 |
| WO2021253335A1 (zh) * | 2020-06-18 | 2021-12-23 | 深圳迈瑞生物医疗电子股份有限公司 | 抗可溶性cd14亚型抗体、试剂盒及其应用 |
| CN116367858A (zh) * | 2020-09-10 | 2023-06-30 | 隐式生物科技有限公司 | 用于治疗心肌梗塞的治疗方法和试剂 |
| AU2021356298A1 (en) | 2020-10-07 | 2023-05-04 | Line 6 Biotechnology, Inc | Methods and agents for the treatment of ocular disease |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117031014A (zh) * | 2023-08-14 | 2023-11-10 | 陕西脉元生物科技有限公司 | 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN118290585B (zh) * | 2024-06-04 | 2024-08-30 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd14工程抗体及应用 |
| CN120399098B (zh) * | 2025-07-03 | 2025-09-16 | 上海玄言生物科技有限公司 | 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0485430T3 (da) * | 1989-08-01 | 1999-06-14 | Scripps Research Inst | Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis |
| US5820858A (en) * | 1993-05-28 | 1998-10-13 | The Scripps Research Institute | Methods and compositions for inhibiting CD14 mediated cell activation |
| ATE308994T1 (de) * | 1994-09-16 | 2005-11-15 | Scripps Research Inst | Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien |
| AU2001290315A1 (en) | 2000-11-22 | 2002-06-03 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| WO2006063292A1 (en) * | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| WO2007059135A2 (en) * | 2005-11-10 | 2007-05-24 | Satoris, Inc. | Methods of treating alzheimer's disease |
| KR101256837B1 (ko) * | 2009-03-09 | 2013-04-22 | 경북대학교 산학협력단 | 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도 |
| JP5894939B2 (ja) * | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2018165720A1 (en) * | 2017-03-17 | 2018-09-20 | Implicit Bioscience Pty Ltd | Agents for treating or preventing viral infections and uses therefor |
| AU2019264996A1 (en) * | 2018-05-10 | 2020-11-26 | The Methodist Hospital | Methods for prognosis and management of disease |
-
2018
- 2018-04-20 IL IL309046A patent/IL309046B2/en unknown
- 2018-04-20 JP JP2020507722A patent/JP2020517740A/ja active Pending
- 2018-04-20 WO PCT/AU2018/050357 patent/WO2018191786A1/en not_active Ceased
- 2018-04-20 US US16/606,727 patent/US20200148780A1/en not_active Abandoned
- 2018-04-20 IL IL270097A patent/IL270097B2/en unknown
- 2018-04-20 EP EP18788123.0A patent/EP3612566A4/en active Pending
- 2018-04-20 AU AU2018255489A patent/AU2018255489B2/en active Active
- 2018-04-20 KR KR1020197033198A patent/KR20200015477A/ko not_active Ceased
- 2018-04-20 CN CN201880040765.4A patent/CN110831975A/zh active Pending
-
2021
- 2021-09-23 US US17/483,517 patent/US12297287B2/en active Active
-
2023
- 2023-04-13 JP JP2023065903A patent/JP2023090751A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517740A5 (https=) | ||
| JP2016513682A5 (https=) | ||
| HRP20200241T1 (hr) | Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti | |
| JP2019522961A5 (https=) | ||
| JP2020513791A5 (https=) | ||
| KR101649168B1 (ko) | 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도 | |
| JP2020517249A5 (https=) | ||
| JP2013500941A5 (https=) | ||
| JP2017113028A5 (https=) | ||
| JP2018512138A5 (https=) | ||
| JP2015530971A5 (https=) | ||
| JP2020536888A5 (https=) | ||
| JP2019054802A5 (https=) | ||
| JP2016508496A5 (https=) | ||
| JP2019110906A5 (https=) | ||
| JP2019527194A5 (https=) | ||
| JP2009519718A5 (https=) | ||
| JP2019505527A5 (https=) | ||
| JP2020502996A5 (https=) | ||
| JP2011514150A5 (https=) | ||
| JP2022537780A5 (https=) | ||
| JP2009540018A5 (https=) | ||
| JP2012504634A5 (https=) | ||
| NZ585559A (en) | Humanized antibodies against tl1a | |
| JP2016136963A5 (https=) |